




CLAIMS

1. A compound of Formula (I):



or a pharmaceutically acceptable salt or solvate thereof, wherein:

F¹ and F² are each independently selected from ring systems A, B, C, and D:



where:

15 each R is independently selected from the group consisting of H, -C₁-C₂₀ alkyl, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, halo, hydroxyl, alkoxy, -NH₂, -NH(C₁-C₈ alkyl), -N(C₁-C₈ alkyl)₂, -NO₂, -C₆-C₁₄ aryl and -C₆-C₁₄ heteroaryl, wherein two or more R optionally join to form a ring or

rings, and wherein said -C₆-C₁₄ aryl and -C₆-C₁₄ heteroaryl are optionally substituted with 1 to 5 substituents independently selected from -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -halo, -C₁-C₁₀ alkylthio, -trifluoromethyl, -NH₂, -NH(C₁-C₈ alkyl), -N(C₁-C₈ alkyl)₂, -C₁-C₁₀ alkyl-N(C₁-C₈ alkyl)₂, -C₁-C₃ alkylthio, -NO₂ or -C₁-C₁₀ heterocyclyl, for each ring system in which R appears;

each V¹ is independently a bond, O, N(R) or S, for each ring system in which V¹ appears;

each V² is independently O, N(R) or S, for each ring system in which V² appears;

W¹ and W² are each independently H, or -C₁-C₅ alkyl for each ring system in which W¹ and W² appear;

10 each X is independently -OH, -O-acyl, azido, halo, cyanate, thiocyanate, isocyanate,

thioisocyanate, or $\begin{array}{c} \text{O} \\ \parallel \\ \text{---O---S---R} \\ \parallel \\ \text{O} \end{array}$, for each ring system in which X appears;


each Y is independently selected from the group consisting of H, -C₁-C₆ alkyl-R^A, -C(O)R^A, -C(S)R^A, -C(O)OR^A, -S(O)₂OR^A, -C(O)N(R^A)₂, -C(S)N(R^A)₂, glycosyl, -NO₂, and -PO(OR^A)₂ for each ring system in which Y appears, wherein each R^A is independently selected from the group consisting of H, -C₁-C₂₀ alkyl, -C₁-C₈ heteroalkyl, -C₆-C₁₄ aryl, aralkyl, -C₁-C₁₀ heterocyclyl, -C₃-C₈ carbocyclyl and -C₁-C₂₀ alkylN(R)₂, wherein said -C₁-C₂₀ alkyl, -C₁-C₈ heteroalkyl, -C₆-C₁₄ aryl, aralkyl, -C₁-C₁₀ heterocyclyl, -C₃-C₈ carbocyclyl and -C₁-C₂₀ alkylN(R)₂ are optionally substituted with 1 to 3 substituents independently selected from R;

each Z is independently selected from the group consisting of H, and -C₁-C₈ alkyl wherein said C₁-C₈ alkyl is optionally substituted with 1 to 3 substituents independently selected from R, for each ring system in which Z appears;

L¹ and L² are each independently a direct bond;

T is selected from:


-C(A¹)X¹-T²-X¹C(B¹)-, where T² is:



wherein each X^1 is independently a bond, wherein A^1 and B^1 are each independently $=O$,
 wherein g and j are each independently 0 and m is 1, and wherein D is $-C_3-C_8$ carbocyclo,
 where said $-C_3-C_8$ carbocyclo is optionally substituted with $-R^E$, $-C(O)R^E$, $-C(O)OR^E$,
 5 $-N(R^E)_2$, $-N(R)C(O)R^E$ or $-N(R)C(O)OR^E$, and D is additionally optionally substituted by 1 to 2
 R , and

wherein each R^E is independently selected from the group consisting of H , $-C_1-C_8$ alkyl,
 $-C_1-C_8$ heteroalkyl, $-C_6-C_{14}$ aryl, $-aralkyl$, $-C_1-C_{10}$ heterocyclyl, $-C_3-C_8$ carbocyclyl,
 $-C(O)OC_1-C_8$ alkyl, $-C(O)N(C_1-C_8 \text{ alkyl})_2$, and $-C(O)-halo$, and wherein each R^E is optionally
 10 substituted with 1 to 3 substituents independently selected from R .

2. A compound of Formula (IIA):





or a pharmaceutically acceptable salt or solvate thereof, wherein:



P is:



wherein:

F^1 and F^2 are each independently selected from ring systems A, B, C, and D:





where:


each R is independently selected from the group consisting of H, -C₁-C₂₀ alkyl, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, halo, hydroxyl, alkoxy, -NH₂, -NH(C₁-C₈ alkyl), -N(C₁-C₈ alkyl)₂, -NO₂, -C₆-C₁₄ aryl and -C₆-C₁₄ heteroaryl, wherein two or more R optionally join to form a ring or rings, and wherein said -C₆-C₁₄ aryl and -C₆-C₁₄ heteroaryl are optionally substituted with 1 to 5 substituents independently selected from -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -halo, -C₁-C₁₀ alkylthio, -trifluoromethyl, -NH₂, -NH(C₁-C₈ alkyl), -N(C₁-C₈ alkyl)₂, -C₁-C₁₀ alkyl-N(C₁-C₈ alkyl)₂, -C₁-C₃ alkylthio, -NO₂ or -C₁-C₁₀ heterocyclyl, for each ring system in which R appears;

each V¹ is independently a bond, O, N(R) or S, for each ring system in which V¹ appears;

each V² is independently O, N(R) or S, for each ring system in which V² appears;

W¹ and W² are each independently H, or -C₁-C₅ alkyl, for each ring system in which W¹ and W² appear;

each X is independently selected from -OH, -O-acyl, azido, halo, cyanate, thiocyanate,

isocyanate, thioisocyanate, or  for each ring system in which X appears;

each Y is independently selected from a bond, H, -C(O)R^A, -C(S)R^A, -C(O)OR^A, -S(O)₂OR^A, -C(O)N(R^A)₂, -C(S)N(R^A)₂, glycosyl, -NO₂, and -P(O)(OR^A)₂ for each ring system in which Y appears, wherein each R^A is independently selected from H, -C₁-C₂₀ alkyl, -C₁-C₈ heteroalkyl, -C₆-C₁₄ aryl, aralkyl, -C₁-C₁₀ heterocyclyl, -C₃-C₈ carbocyclyl, -C₁-C₂₀ alkylN(R)₂, -C₁-C₂₀ alkylene, -C₁-C₈ heteroalkylene, -C₆-C₁₄ arylene, aralkylene, -C₁-C₁₀ heterocyclo, -C₃-C₈ carbocyclo and -C₁-C₂₀ alkylN(R)-, and R^F where said R^A is optionally substituted with

1 to 3 substituents independently selected from R, and wherein one Y is divalent and is bonded to L,


R^F is $-N(R^6)QN(R^5)C(O)-$ and is bonded to L at the carbonyl adjacent $N(R^5)$, wherein R^5 and R^6 are each independently selected from the group consisting of H, $-C_1-C_8$ alkyl, $-C_1-C_8$ heteroalkyl, $-C_6-C_{14}$ aryl, -aralkyl, $-C_1-C_{10}$ heterocyclyl and $-C_3-C_8$ carbocyclyl, or R^5 or R^6 joins with a substituted carbon on Q to form a $-C_1-C_{10}$ heterocyclic or $-C_6-C_{14}$ heteroaryl ring, or R^5 and R^6 join together to form a $-C_1-C_{10}$ heterocyclic or $-C_6-C_{14}$ heteroaryl ring system, and where Q is $-C_1-C_8$ alkylene-, $-C_1-C_8$ heteroalkylene-, $-C_6-C_{14}$ arylene-, -aralkylene-, $-C_1-C_{10}$ heterocyclo- or $-C_3-C_8$ carbocyclo-, wherein Q, R^5 and R^6 are each independently optionally substituted with 1 to 3 substituents independently selected from R;

each Z is independently selected from the group consisting of H, and $-C_1-C_8$ alkyl and wherein said C_1-C_8 alkyl, is optionally substituted with 1 to 3 substituents independently selected from R, for each ring system in which Z appears;

L^1 and L^2 are each independently a direct bond;

T is selected from:


$-C(A^1)X^1-T^2-X^1C(B^1)-$, where T^2 is:



wherein each X^1 is independently a bond, wherein A^1 and B^1 are each independently $=O$, wherein g and j are each independently 0 and m is 1, and wherein D is $-C_3-C_8$ carbocyclo, where said $-C_3-C_8$ carbocyclo is optionally substituted with $-R^E$, $-C(O)R^E$, $-C(O)OR^E$, $-N(R^E)_2$, $-N(R)C(O)R^E$ or $-N(R)C(O)OR^E$, and D is additionally optionally substituted by 1 to 2 R;

wherein each R^E is independently selected from the group consisting of H, $-C_1-C_8$ alkyl, $-C_1-C_8$ heteroalkyl, -aryl, -aralkyl, $-C_1-C_{10}$ heterocyclyl, $-C_3-C_8$ carbocyclyl, $-C(O)OC_1-C_8$ alkyl, $-C(O)N(C_1-C_8 \text{ alkyl})_2$, and $-C(O)$ -halo, and wherein each R^E is optionally substituted with 1 to 3 substituents independently selected from R;

L is $L^A-L^B-(L^C)_{1-3}$, wherein L^A is selected from the group consisting of -halo, $-N(R)_2$, $-CON(R)_2$, -S-aryl optionally substituted with $-NO_2$ or $-CON(R)_2$, -S-heteroaryl optionally substituted with $-NO_2$, alkyl-SO₂-heteroaryl, arylSO₂-heteroaryl-,



- 5 L^B is $L^{B1}-L^{B2}-L^{B3}$ wherein L^{B1} is absent or is one or more components selected from the group consisting of $-C(O)-$, $-C(S)-$, $-C(O)NR-$, $-C(O)C_1-C_6alkyl-$, $-C(O)NRC_1-C_6alkyl-$, $-C_1-C_6alkyl(OCH_2CH_2)_{1-6}-$, $-C(O)C_1-C_6alkylNRC(O)-$, $-C(O)C_1-C_6alkyl(OCH_2CH_2)_{1-6}-$, $-C_1-C_6alkyl(OCH_2CH_2)_{1-6}-C(O)-$, $-C_1-C_6alkyl-S-S-C_1-C_6alkylNRC(O)CH_2-$, $-C_1-C_6alkyl(OCH_2CH_2)_{1-6}NRC(O)CH_2-$, $-C(O)C_1-C_6alkyl-NRC(O)C_1-C_6alkyl-$,
 10 $-N=CR-phenyl-O-C_1-C_6alkyl-$, $-N=CR-phenyl-O-C_1-C_6alkyl-C(O)-$, $-C(O)-C_1-C_6alkyl(OCH_2CH_2)_{1-6}NRC(O)-$, $-C(O)C_1-C_6alkyl-phenyl(NR-C(O)C_1-C_6alkyl)_{1-4}-$, $-C(O)C_1-C_6alkyl(OCH_2CH_2)_{1-6}-NRC(O)C_1-C_6alkyl-$, $-C_1-C_6alkyl-$, $-S-$, $-C(O)-CH(NR-C(O)C_1-C_6alkyl)-C_1-C_6alkyl-$ and $(-CH_2-CH_2-O-)_{1-20}$,


wherein L^{B2} is AA_{0-12} , wherein AA is a natural amino acid, a non-natural amino acid or

- 15 $-(CR^{15})_o-S-S-(CR^{15})_p$ where o and p are each independently an integer from 1 to 20,

L^{B3} is -PABA-, -PABC-, $-C(O)(CH_2)_nC(O)-$ or absent;

L^C is absent or independently selected from the group consisting of $-C_1-C_6alkylene-$, $-NRC_3-C_8-heterocyclylNR-$, $-NRC_3-C_8-carbocyclylNR-$, $-NRC_1-C_6alkylNR-$, $-NRC_1-C_6alkylene-$, $-S-$, $-NR-$, $-NRNR-$, $-O(CR_2)_{1-4}S-S(CR_2)_{1-4}N(R)-$,

- 20 $-NRC_1-C_6-alkylenephényleneNR-$, $-NRC_1-C_6alkylenephényleneSO_2NR-$, $-OC_1-C_6alkylS-SC_1-C_6alkylC(COOR)NR-$, $-NRC(COOR)C_1-C_6alkylS-SC_1-C_6alkylO-$,



wherein

X^A is CR or N ,

X^B is CH, $CR(C(R)_2)_{1-3}NR$, $CR(C(R)_2)_{1-3}O$, $CR(C(R)_2)_{1-3}C(O)NR$, $CR-(C(R)_2)_{1-3}C(O)NRNR$,
 5 $CR(C(R)_2)_{1-3}SO_2NR$, $CR(C(R)_2)_{1-3}NRNR$, $CR(C(R)_2)_{1-3}NRC(O)$ or N,

each X^C is R,


each X^D is $-(CH_2)_{1-5}-$, or is absent;

X^E is O, S, $C(R)_2$, $C(R)(C(R)_2)_{1-3}-NR_2$ or NR and

each X^F is $(C(R)_2)_{1-3}-NR$ or $C(R)_2-(C(R)_2)_{1-3}-O$.

10

3. A compound of Formula (IIIA):



or a pharmaceutically acceptable salt or solvate thereof, wherein:





AB is an antibody;

15 P is:



wherein:

F¹ and F² are each independently selected from ring systems A, B, C, and D:



5

where:

each R is independently selected from the group consisting of H, -C₁-C₂₀ alkyl, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, halo, hydroxyl, alkoxy, -NH₂, -NH(C₁-C₈ alkyl), -N(C₁-C₈ alkyl)₂, -NO₂,
 10 -C₆-C₁₄ aryl and -C₆-C₁₄ heteroaryl, wherein two or more R optionally join to form a ring or rings, and wherein said -C₆-C₁₄ aryl and -C₆-C₁₄ heteroaryl are optionally substituted with 1 to 5 substituents independently selected from -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -halo, -C₁-C₁₀ alkylthio, -trifluoromethyl, -NH₂, -NH(C₁-C₈ alkyl), -N(C₁-C₈ alkyl)₂, -C₁-C₁₀ alkyl-N(C₁-C₈ alkyl)₂, -C₁-C₃ alkylthio, -NO₂ or -C₁-C₁₀ heterocyclyl, for each ring system in which R
 15 appears;

each V¹ is independently a bond, O, N(R) or S, for each ring system in which V¹ appears;

each V² is independently O, N(R) or S, for each ring system in which V² appears;

W^1 and W^2 are each independently H, or $-C_1-C_5$ alkyl for each ring system in which W^1 and W^2 appear;

each X is independently selected from -OH, -O-acyl, azido, halo, cyanate, thiocyanate,

isocyanate, thioisocyanate, or $\begin{array}{c} \text{O} \\ \parallel \\ \text{---O---S---R} \\ \parallel \\ \text{O} \end{array}$, for each ring system in which X appears;

- 5 each Y is independently selected from a bond, H, $-C(O)R^A$, $-C(S)R^A$, $-C(O)OR^A$, $-S(O)_2OR^A$, $-C(O)N(R^A)_2$, $-C(S)N(R^A)_2$, glycosyl, $-NO_2$, and $-P(O)(OR^A)_2$ for each ring system in which Y appears, wherein each R^A is independently selected from H, $-C_1-C_{20}$ alkyl, $-C_1-C_8$ heteroalkyl, $-C_6-C_{14}$ aryl, aralkyl, $-C_1-C_{10}$ heterocyclyl, $-C_3-C_8$ carbocyclyl, $-C_1-C_{20}$ alkylN(R)₂, $-C_1-C_{20}$ alkylene, $-C_1-C_8$ heteroalkylene, $-C_6-C_{14}$ arylene, aralkylene, $-C_1-C_{10}$ heterocyclo,
- 10 $-C_3-C_8$ carbocyclo and $-C_1-C_{20}$ alkylN(R)-, and R^F where said R^A is optionally substituted with 1 to 3 substituents independently selected from R, and wherein one Y is divalent and is bonded to L,


- R^F is $-N(R^6)QN(R^5)C(O)-$ and is bonded to L at the carbonyl adjacent N(R^5), wherein R^5 and R^6 are each independently selected from the group consisting of H, $-C_1-C_8$ alkyl, $-C_1-C_8$ heteroalkyl, $-C_6-C_{14}$ aryl, -aralkyl, $-C_1-C_{10}$ heterocyclyl and $-C_3-C_8$ carbocyclyl, or R^5 or R^6
- 15 joins with a substituted carbon on Q to form a $-C_1-C_{10}$ heterocyclic or $-C_6-C_{14}$ heteroaryl ring, or R^5 and R^6 join together to form a $-C_1-C_{10}$ heterocyclic or $-C_6-C_{14}$ heteroaryl ring system, and where Q is $-C_1-C_8$ alkylene-, $-C_1-C_8$ heteroalkylene-, $-C_6-C_{14}$ arylene-, -aralkylene-, $-C_1-C_{10}$ heterocyclo- or $-C_3-C_8$ carbocyclo-, wherein Q, R^5 and R^6 are each independently
- 20 optionally substituted with 1 to 3 substituents independently selected from R;

each Z is independently selected from the group consisting of H, and $-C_1-C_8$ alkyl and wherein said C_1-C_8 alkyl is optionally substituted with 1 to 3 substituents independently selected from R, for each ring system in which Z appears;

L^1 and L^2 are each independently a direct bond;

- 25 T is selected from:

$-C(A^1)X^1-T^2-X^1C(B^1)-$, where T^2 is:




wherein each X^1 is independently a bond, wherein A^1 and B^1 are each independently $=O$,
 wherein g and j are each independently 0 and m is 1, and wherein D is $-C_3-C_8$ carbocyclo,
 where said $-C_3-C_8$ carbocyclo is optionally substituted with $-R^E$, $-C(O)R^E$, $-C(O)OR^E$,
 5 $-N(R^E)_2$, $-N(R)C(O)R^E$ or $-N(R)C(O)OR^E$, and D is additionally optionally substituted by 1 to 2
 R ;

wherein each R^E is independently selected from the group consisting of H , $-C_1-C_8$ alkyl,
 $-C_1-C_8$ heteroalkyl, -aryl, -aralkyl, $-C_1-C_{10}$ heterocyclyl, $-C_3-C_8$ carbocyclyl, $-C(O)OC_1-C_8$ alkyl,
 $-C(O)N(C_1-C_8 \text{ alkyl})_2$, and $-C(O)$ -halo, and wherein each R^E is optionally substituted with 1 to
 10 3 substituents independently selected from R ;

L is $L^A-L^B-(L^C)_{1-3}$;

L^A is selected from: a bond to AB , $-NR$ -(bond to AB),




L^B is $L^{B1}-L^{B2}-L^{B3}$

15 wherein L^{B1} is absent or is one or more components selected from the group consisting of
 $-C(O)-$, $-C(S)-$, $-C(O)NR-$, $-C(O)C_1-C_6$ alkyl-, $-C(O)NRC_1-C_6$ alkyl-, $-C_1-C_6$ alkyl(OCH_2CH_2) $_{1-6}-$,
 $-C(O)C_1-C_6$ alkylNRC(O)-, $-C(O)C_1-C_6$ alkyl(OCH_2CH_2) $_{1-6}-$, $-C_1-C_6$ alkyl(OCH_2CH_2) $_{1-6}-C(O)-$,
 $-C_1-C_6$ alkyl-S-S- C_1-C_6 alkylNRC(O)CH $_2-$, $-C_1-C_6$ alkyl(OCH_2CH_2) $_{1-6}$ NRC(O)CH $_2-$,
 $-C(O)C_1-C_6$ alkyl-NRC(O)C $_1-C_6$ alkyl-, $-N=CR$ -phenyl-O- C_1-C_6 alkyl-,
 20 $-N=CR$ -phenyl-O- C_1-C_6 alkyl-C(O)-, $-C(O)-C_1-C_6$ alkyl(OCH_2CH_2) $_{1-6}$ NRC(O)-,
 $-C(O)C_1-C_6$ alkyl-phenyl(NR-C(O)C $_1-C_6$ alkyl) $_{1-4}-$,
 $-C(O)C_1-C_6$ alkyl(OCH_2CH_2) $_{1-6}$ -NRC(O)C $_1-C_6$ alkyl-, $-C_1-C_6$ alkyl-, $-S-$, $-C(O)-CH(NR-C(O)C_1-$
 C_6 alkyl)- C_1-C_6 alkyl- and $(-CH_2-CH_2-O-)$ $_{1-20}$;

L^{B2} is AA_{0-12} , wherein AA is a natural amino acid, a non-natural amino acid or $-(CR^{15})_o-S-S-(CR^{15})_p$ where o and p are each independently an integer from 1 to 20,

L^{B3} is -PABA-, -PABC-, $-C(O)(CH_2)_nC(O)-$ or absent,

- 5 L^C is absent or is independently selected from the group consisting of $-C_1-C_6$ alkylene-, $-NRC_3-C_8$ -heterocyclylNR-, $-NRC_3-C_8$ -carbocyclylNR-, $-NRC_1-C_6$ alkylNR-, $-NRC_1-C_6$ alkylene-, -S-, -NR-, -NRNR-, $-O(CR_2)_{1-4}S-S(CR_2)_{1-4}N(R)-$, $-NRC_1-C_6$ -alkylenephenyleneNR-, $-NRC_1-C_6$ alkylenephenyleneSO₂NR-, $-OC_1-C_6$ alkylS-SC_{1-C6}alkylC(COOR)NR-, $-NRC(COOR)C_1-C_6$ alkylS-SC_{1-C6}alkylO-,



- 10 wherein

X^A is CR or N,

X^B is CH, $CR(C(R)_2)_{1-3}NR$, $CR(C(R)_2)_{1-3}O$, $CR(C(R)_2)_{1-3}C(O)NR$, $CR-(C(R)_2)_{1-3}C(O)NRNR$, $CR(C(R)_2)_{1-3}SO_2NR$, $CR(C(R)_2)_{1-3}NRNR$, $CR(C(R)_2)_{1-3}NRC(O)$ or N,


each X^C is R;

- 15 each X^D is $-(CH_2)_{1-5}-$, or is absent;

X^E is O, S, $C(R)_2$, $C(R)(C(R)_2)_{1-3}NR_2$ or NR, and





each X^F is $(C(R)_2)_{1-3}NR$ or $C(R)_2-(C(R)_2)_{1-3}O$.

4. A compound of Formula (IIB):



or a pharmaceutically acceptable salt or solvate thereof, wherein:

F¹ and F² are each independently selected from ring systems A, B, C, and D:



where:

each R is independently selected from the group consisting of H, -C₁-C₂₀ alkyl, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, halo, hydroxyl, alkoxy, -NH₂, -NH(C₁-C₈ alkyl), -N(C₁-C₈ alkyl)₂, -NO₂, -C₆-C₁₄ aryl and -C₆-C₁₄ heteroaryl, wherein two or more R optionally join to form a ring or rings, and wherein said -C₆-C₁₄ aryl and -C₆-C₁₄ heteroaryl are optionally substituted with 1 to 5 substituents independently selected from -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -halo, -C₁-C₁₀ alkylthio, -trifluoromethyl, -NH₂, -NH(C₁-C₈ alkyl), -N(C₁-C₈ alkyl)₂, -C₁-C₁₀ alkyl-N(C₁-C₈ alkyl)₂, -C₁-C₃ alkylthio, -NO₂ or -C₁-C₁₀ heterocyclyl, for each ring system in which R appears;

each V¹ is independently a bond, O, N(R) or S, for each ring system in which V¹ appears;

each V² is independently O, N(R) or S, for each ring system in which V² appears;

W^1 and W^2 are each independently H, or $-C_1-C_5$ alkyl;

each X is independently -OH, -O-acyl, azido, halo, cyanate, thiocyanate, isocyanate,

thioisocyanate, or $\begin{array}{c} \text{O} \\ \parallel \\ \text{---O---S---R} \\ \parallel \\ \text{O} \end{array}$, for each ring system in which X appears;


each Y is independently selected from the group consisting of H, $-C_1-C_6$ alkyl- R^A $-C(O)R^A$,
 5 $-C(S)R^A$, $-C(O)OR^A$, $-S(O)_2OR^A$, $-C(O)N(R^A)_2$, $-C(S)N(R^A)_2$, glycosyl, $-NO_2$, and $-PO(OR^A)_2$ for
 each ring system in which Y appears, wherein each R^A is independently selected from the
 group consisting of H, $-C_1-C_{20}$ alkyl, $-C_1-C_8$ heteroalkyl, $-C_6-C_{14}$ aryl, aralkyl, $-C_1-C_{10}$
 heterocyclyl, $-C_3-C_8$ carbocyclyl and $-C_1-C_{20}$ alkylN(R)₂, wherein said $-C_1-C_{20}$ alkyl, $-C_1-C_8$
 heteroalkyl, $-C_6-C_{14}$ aryl, aralkyl, $-C_1-C_{10}$ heterocyclyl, $-C_3-C_8$ carbocyclyl and $-C_1-C_{20}$
 10 alkylN(R)₂ are optionally substituted with 1 to 3 substituents independently selected from R;

each Z is independently selected from the group consisting of H, and $-C_1-C_8$ alkyl, wherein
 said $-C_1-C_8$ alkyl is optionally substituted with 1 to 3 substituents independently selected from
 R, for each ring system in which Z appears;

L^1 and L^2 are each independently a direct bond;

15 T is selected from:

$-C(A^1)X^1-T^2-X^1C(B^1)-$, where T^2 is:




wherein each X^1 is independently a bond, wherein A^1 and B^1 are each independently =O,
 wherein g and j are each independently 0 and m is 1, and wherein D is $-C_3-C_8$ carbocyclo,
 20 where said $-C_3-C_8$ carbocyclo is substituted with one member of the group selected from
 $N(R^E)C(O)-$ where the carbonyl is bonded to L, and $-C(O)-$ where the carbonyl is bonded to
 L, and additionally optionally substituted by 1 to 2 R;

where each R^E is independently selected from the group consisting of H, $-C_1-C_8$ alkyl, $-C_1-C_8$
 heteroalkyl, -aryl, -aralkyl, $-C_1-C_{10}$ heterocyclyl, $-C_3-C_8$ carbocyclyl, $-C(O)OC_1-C_8$ alkyl,

-C(O)N(C₁-C₈ alkyl)₂, and -C(O)-halo, and wherein each R^E is optionally substituted with 1 to 3 substituents independently selected from R;

L is L^A-L^B-(L^C)₁₋₃;

L^A is selected from -halo, -N(R)₂, -CON(R)₂, -S-aryl optionally substituted with -NO₂ or -CONR₂, -S-heteroaryl optionally substituted with -NO₂, alkyl-SO₂-heteroaryl, arylSO₂-heteroaryl-,




L^B is L^{B1}-L^{B2}-L^{B3}

wherein L^{B1} is absent or is one or more components selected from the group consisting of
 -C(O)-, -C(S)-, -C(O)NR-, -C(O)C₁-C₆alkyl-, -C(O)NRC₁-C₆alkyl-, -C₁-C₆alkyl(OCH₂CH₂)₁₋₆-,
 -C(O)C₁-C₆alkylNRC(O)-, -C(O)C₁-C₆alkyl(OCH₂CH₂)₁₋₆-, -C₁-C₆alkyl(OCH₂CH₂)₁₋₆-C(O)-,
 -C₁-C₆alkyl-S-S-C₁-C₆alkylNRC(O)CH₂-, -C₁-C₆alkyl(OCH₂CH₂)₁₋₆NRC(O)CH₂-,
 -C(O)C₁-C₆alkyl-NRC(O)C₁₋₆alkyl-, -N=CR-phenyl-O-C₁-C₆alkyl-,
 -N=CR-phenyl-O-C₁-C₆alkyl-C(O)-, -C(O)-C₁-C₆alkyl(OCH₂CH₂)₁₋₆NRC(O)-,
 -C(O)C₁-C₆alkyl-phenyl(NR-C(O)C₁-C₆alkyl)₁₋₄-,
 -C(O)C₁-C₆alkyl(OCH₂CH₂)₁₋₆-NRC(O)C₁-C₆alkyl-, -C₁-C₆alkyl-, -S-, -C(O)-CH(NR-C(O)C₁-
 C₆alkyl)-C₁-C₆alkyl- and (-CH₂-CH₂-O)₁₋₂₀;

L^{B2} is AA₀₋₁₂, wherein AA is a natural amino acid, a non-natural amino acid or -(CR¹⁵)_o-S-S-(CR¹⁵)_p where o and p are each independently an integer from 1 to 20,

L^{B3} is -PABA-, -PABC-, -C(O)(CH₂)_nC(O)- or absent;

L^C is absent or is independently selected from the group consisting of -C₁-C₆alkylene-,
 -NRC₃-C₈-heterocyclylNR-, -NRC₃-C₈-carbocyclylNR-, -NRC₁-C₆alkylNR-,
 -NRC₁-C₆alkylene-, -S-, -NR-, -NRNR-, -O(CR₂)₁₋₄S-S(CR₂)₁₋₄N(R)-,
 -NRC₁-C₆-alkylenephenyleneNR-, -NRC₁-C₆alkylenephenyleneSO₂NR-,
 -OC₁-C₆alkylS-SC₁-C₆alkylC(COOR)NR-, -NRC(COOR)C₁-C₆alkylS-SC₁-C₆alkylO-,



wherein

X^A is CR or N,

X^B is CH, $CR(C(R)_2)_{1-3}NR$, $CR(C(R)_2)_{1-3}O$, $CR(C(R)_2)_{1-3}C(O)NR$, $CR-(C(R)_2)_{1-3}C(O)NRNR$,
 5 $CR(C(R)_2)_{1-3}SO_2NR$, $CR(C(R)_2)_{1-3}NRNR$, $CR(C(R)_2)_{1-3}NRC(O)$ or N;


each X^C is R;

each X^D is $-(CH_2)_{1-5}-$, or is absent;

X^E is O, S, $C(R)_2$, $C(R)(C(R)_2)_{1-3}NR_2$ or NR, and

each X^F is $(C(R)_2)_{1-3}NR$ or $C(R)_2-(C(R)_2)_{1-3}O$.





10 5. A compound of Formula (IIIB):



or a pharmaceutically acceptable salt or solvate thereof, wherein:

AB is an antibody;

F^1 and F^2 are each independently selected from ring systems A, B, C, and D:



5 where:

each R is independently selected from the group consisting of H, -C₁-C₂₀ alkyl, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, halo, hydroxyl, alkoxy, -NH₂, -NH(C₁-C₈ alkyl), -N(C₁-C₈ alkyl)₂, -NO₂, -C₆-C₁₄ aryl and -C₆-C₁₄ heteroaryl, wherein two or more R optionally join to form a ring or rings, and wherein said -C₆-C₁₄ aryl and -C₆-C₁₄ heteroaryl are optionally substituted with 1
10 to 5 substituents independently selected from -C₁-C₁₀ alkyl, -C₁-C₁₀ alkoxy, -halo, -C₁-C₁₀ alkylthio, -trifluoromethyl, -NH₂, -NH(C₁-C₈ alkyl), -N(C₁-C₈ alkyl)₂, -C₁-C₁₀ alkyl-N(C₁-C₈ alkyl)₂, -C₁-C₃ alkylthio, -NO₂ or -C₁-C₁₀ heterocyclyl, for each ring system in which R appears;

each V¹ is independently a bond, O, N(R) or S, for each ring system in which V¹ appears;

15 each V² is independently O, N(R) or S, for each ring system in which V² appears;

W¹ and W² are each independently H, or -C₁-C₅ alkyl for each ring system in which W¹ and W² appear;

each X is independently -OH, -O-acyl, azido, halo, cyanate, thiocyanate, isocyanate,


thioisocyanate, or $\begin{array}{c} \text{O} \\ \parallel \\ \text{---O---S---R} \\ \parallel \\ \text{O} \end{array}$, for each ring system in which X appears;

- each Y is independently selected from the group consisting of H, -C₁-C₆ alkyl-R^A, -C(O)R^A, -C(S)R^A, -C(O)OR^A, -S(O)₂OR^A, -C(O)N(R^A)₂, -C(S)N(R^A)₂, glycosyl, and -PO(OR^A)₂ for each
- 5 ring system in which Y appears, wherein each R^A is independently selected from the group consisting of H, -C₁-C₂₀ alkyl, -C₁-C₈ heteroalkyl, -C₆-C₁₄ aryl, aralkyl, -C₁-C₁₀ heterocyclyl, -C₃-C₈ carbocyclyl and -C₁-C₂₀ alkylN(R)₂, wherein said -C₁-C₂₀ alkyl, -C₁-C₈ heteroalkyl, -C₆-C₁₄ aryl, aralkyl, -C₁-C₁₀ heterocyclyl, -C₃-C₈ carbocyclyl and -C₁-C₂₀ alkylN(R)₂ are optionally substituted with 1 to 3 substituents independently selected from R;
- 10 each Z is independently selected from the group consisting of H, and -C₁-C₈ alkyl wherein said C₁-C₈ alkyl is optionally substituted with 1 to 3 substituents independently selected from R, for each ring system in which Z appears;

L¹ and L² are each independently a direct bond;

T is selected from:

- 15 -C(A¹)X¹-T²-X¹C(B¹)-, where T² is:




- wherein each X¹ is independently a bond, wherein A¹ and B¹ are each independently =O, wherein g and j are each independently 0 and m is 1, and wherein D is -C₃-C₈ carbocyclo, where said -C₃-C₈ carbocyclo is substituted with one member of the group selected from
- 20 N(R^E)C(O)- where the carbonyl is bonded to L, and -C(O)- where the carbonyl is bonded to L, and additionally optionally substituted by 1 to 2 R;

- where each R^E is independently selected from the group consisting of H, -C₁-C₈ alkyl, -C₁-C₈ heteroalkyl, -aryl, -aralkyl, -C₁-C₁₀ heterocyclyl, -C₃-C₈ carbocyclyl, -C(O)OC₁-C₈ alkyl, -C(O)N(C₁-C₈ alkyl)₂, and -C(O)-halo, and wherein each R^E is optionally substituted with 1 to
- 25 3 substituents independently selected from R;

L is $L^A-L^B-(L^C)_{1-3}$;

L^A is selected from: a bond to AB, -NR-(bond to AB),



L^B is $L^{B1}-L^{B2}-L^{B3}$

- 5 wherein L^{B1} is absent or is one or more components selected from the group consisting of
 -C(O)-, -C(S)-, -C(O)NR-, -C(O)C₁-C₆alkyl-, -C(O)NRC₁-C₆alkyl-, -C₁-C₆alkyl(OCH₂CH₂)₁₋₆-,
 -C(O)C₁-C₆alkylNRC(O)-, -C(O)C₁-C₆alkyl(OCH₂CH₂)₁₋₆-, -C₁-C₆alkyl(OCH₂CH₂)₁₋₆-C(O)-,
 -C₁-C₆alkyl-S-S-C₁-C₆alkylNRC(O)CH₂-, -C₁-C₆alkyl(OCH₂CH₂)₁₋₆NRC(O)CH₂-,
 -C(O)C₁-C₆alkyl-NRC(O)C₁₋₆alkyl-, -N=CR-phenyl-O-C₁-C₆alkyl-,
 10 -N=CR-phenyl-O-C₁-C₆alkyl-C(O)-, -C(O)-C₁-C₆alkyl(OCH₂CH₂)₁₋₆NRC(O)-,
 -C(O)C₁-C₆alkyl-phenyl(NR-C(O)C₁-C₆alkyl)₁₋₄-,
 -C(O)C₁-C₆alkyl(OCH₂CH₂)₁₋₆NRC(O)C₁-C₆alkyl-, -C₁-C₆alkyl-, -S-, -C(O)-CH(NR-C(O)C₁-
 C₆alkyl)-C₁-C₆alkyl- and (-CH₂-CH₂-O-)₁₋₂₀;


L^{B2} is AA₀₋₁₂, wherein AA is a natural amino acid, a non-natural amino acid or

- 15 -(CR¹⁵)_o-S-S-(CR¹⁵)_p where o and p are each independently an integer from 1 to 20,

L^{B3} is -PABA-, -PABC-, -C(O)(CH₂)_nC(O)- or absent;

L^C is absent or is independently selected from the group consisting of -C₁-C₆alkylene-,

- NRC₃-C₈-heterocyclINR-, -NRC₃-C₈-carbocyclINR-, -NRC₁-C₆alkylINR-,
 -NRC₁-C₆alkylene-, -S-, -NR-, -NRNR-, -O(CR₂)₁₋₄S-S(CR₂)₁₋₄N(R)-,
 20 -NRC₁-C₆-alkylenephenyleneNR-, -NRC₁-C₆alkylenephenyleneSO₂NR-,
 -OC₁-C₆alkylS-SC₁-C₆alkylC(COOR)NR-, -NRC(COOR)C₁-C₆alkylS-SC₁-C₆alkylO-,



and

wherein

X^A is CR or N,

X^B is CH, $CR(C(R)_2)_{1-3}NR$, $CR(C(R)_2)_{1-3}O$, $CR(C(R)_2)_{1-3}C(O)NR$, $CR-(C(R)_2)_{1-3}C(O)NRNR$,
 5 $CR(C(R)_2)_{1-3}SO_2NR$, $CR(C(R)_2)_{1-3}NRNR$, $CR(C(R)_2)_{1-3}NRC(O)$ or N;

each X^C is R;

each X^D is $-(CH_2)_{1-5}-$, or is absent;

X^E is O, S, $C(R)_2$, $C(R)(C(R)_2)_{1-3}NR_2$ or NR, and

each X^F is $(C(R)_2)_{1-3}NR$ or $C(R)_2-(C(R)_2)_{1-3}O$.

10 6. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein:

each R is independently selected from the group consisting of H, $-C_1-C_{20}$ alkyl and $-NH_2$;

each V^1 is independently O or N(R) for each ring system in which V^1 appears;

each V^2 is independently O or N(R) for each ring system in which V^2 appears;

15 W^1 and W^2 are each independently H, or $-C_1-C_5$ alkyl for each ring system in which W^1 and W^2 appear;


each X is independently halo, for each ring system in which X appears;

each Y is independently selected from the group consisting of H, $-\text{C}(\text{O})\text{R}^{\text{A}}$, $-\text{C}(\text{O})\text{N}(\text{R}^{\text{A}})_2$, glycosyl, $-\text{NO}_2$, and $-\text{PO}(\text{OR}^{\text{A}})_2$ for each ring system in which Y appears, wherein each R^{A} is independently selected from the group consisting of H, $-\text{C}_1\text{-C}_{20}$ alkyl, $-\text{C}_1\text{-C}_8$ heteroalkyl, $-\text{C}_3\text{-C}_8$ carbocyclyl and $-\text{C}_1\text{-C}_{20}$ alkyl $\text{N}(\text{R})_2$, wherein said $-\text{C}_1\text{-C}_{20}$ alkyl, $-\text{C}_1\text{-C}_8$ heteroalkyl, $-\text{C}_3\text{-C}_8$ carbocyclyl and $-\text{C}_1\text{-C}_{20}$ alkyl $\text{N}(\text{R})_2$ are optionally substituted with 1 to 3 substituents independently selected from R;

L^1 and L^2 are each independently direct bond; and

T is selected from:

$-\text{C}(\text{A}^1)\text{X}^1\text{-T}^2\text{-X}^1\text{C}(\text{B}^1)-$, where T^2 is:



wherein each X^1 is a bond, wherein A^1 and B^1 are each independently $=\text{O}$, wherein g and j are each independently 0 and m is 1, and wherein D is $-\text{C}_3\text{-C}_8$ carbocyclo, where said $-\text{C}_3\text{-C}_8$ carbocyclo is optionally substituted with $-\text{NH}_2$, $-\text{N}(\text{R})\text{C}(\text{O})\text{H}$ or $-\text{N}(\text{R})\text{C}(\text{O})\text{OH}$.

7. The compound of any of claims 2-3, or a pharmaceutically acceptable salt or solvate thereof, wherein:

each R is independently selected from the group consisting of H, $-\text{C}_1\text{-C}_{20}$ alkyl and $-\text{NH}_2$;

each V^1 is independently O or $\text{N}(\text{R})$ for each ring system in which V^1 appears;

each V^2 is independently O or $\text{N}(\text{R})$ for each ring system in which V^2 appears;

W^1 and W^2 are each independently H, or $-\text{C}_1\text{-C}_5$ alkyl for each ring system in which W^1 and W^2 appear;

each X is independently halo, for each ring system in which X appears;

each Y is independently selected from a bond, H, $-\text{C}(\text{O})\text{R}^{\text{A}}$, $-\text{C}(\text{S})\text{R}^{\text{A}}$, $-\text{C}(\text{O})\text{OR}^{\text{A}}$, $-\text{S}(\text{O})_2\text{OR}^{\text{A}}$, $-\text{C}(\text{O})\text{N}(\text{R}^{\text{A}})_2$, $-\text{C}(\text{S})\text{N}(\text{R}^{\text{A}})_2$, glycosyl, $-\text{NO}_2$, and $-\text{P}(\text{O})(\text{OR}^{\text{A}})_2$ for each ring system in which Y


appears, wherein each R^A is independently selected from H, $-C_1-C_{20}$ alkyl, $-C_1-C_8$ heteroalkyl, $-C_6-C_{14}$ aryl, aralkyl, $-C_1-C_{10}$ heterocyclyl, $-C_3-C_8$ carbocyclyl, $-C_1-C_{20}$ alkylN(R)₂, $-C_1-C_{20}$ alkylene, $-C_1-C_8$ heteroalkylene, $-C_6-C_{14}$ arylene, aralkylene, $-C_1-C_{10}$ heterocyclo, $-C_3-C_8$ carbocyclo and $-C_1-C_{20}$ alkylN(R)-, and R^F where said R^A is optionally substituted with 1 to 3 substituents independently selected from R, and wherein one Y is divalent and is bonded to L,

R^F is $-N(R^6)QN(R^5)C(O)-$ and is bonded to L at the carbonyl adjacent N(R⁵), wherein R^5 and R^6 are each independently selected from the group consisting of H, $-C_1-C_8$ alkyl, and $-C_1-C_8$ heteroalkyl, or R^5 or R^6 joins with a substituted carbon on Q to form a $-C_1-C_{10}$ heterocyclic or $-C_6-C_{14}$ heteroaryl ring, or R^5 and R^6 join together to form a $-C_1-C_{10}$ heterocyclic or $-C_6-C_{14}$ heteroaryl ring system, and where Q is $-C_1-C_8$ alkylene-, $-C_6-C_{14}$ arylene-, or $-C_3-C_8$ carbocyclo-, wherein Q, R^5 and R^6 are each independently optionally substituted with 1 to 3 substituents independently selected from R;

L^1 and L^2 are each independently a direct bond; and

T is selected from:

$-C(A^1)X^1-T^2-X^1C(B^1)-$, where T^2 is:



wherein each X^1 is a bond, wherein A^1 and B^1 are each independently =O, wherein g and j are each independently 0 and m is 1, and wherein D is $-C_3-C_8$ carbocyclo, where said $-C_3-C_8$ carbocyclo is optionally substituted with $-NH_2$, $-N(R)C(O)H$ or $-N(R)C(O)OH$.

8. The compound of any of claims 4-5, or a pharmaceutically acceptable salt or solvate thereof, wherein:

each R is independently selected from the group consisting of H, $-C_1-C_{20}$ alkyl and $-NH_2$;

each V^1 is independently O or N(R) for each ring system in which V^1 appears;

each V^2 is independently O or N(R) for each ring system in which V^2 appears;


W^1 and W^2 are each independently H, or $-C_1-C_5$ alkyl for each ring system in which W^1 and W^2 appear;

each X is independently halo, for each ring system in which X appears;

5 each Y is independently selected from the group consisting of H, $-C(O)R^A$, $-C(O)N(R^A)_2$, glycosyl, $-NO_2$, and $-PO(OR^A)_2$ for each ring system in which Y appears, wherein each R^A is independently selected from the group consisting of H, $-C_1-C_{20}$ alkyl, $-C_1-C_8$ heteroalkyl, $-C_3-C_8$ carbocyclyl and $-C_1-C_{20}$ alkyl $N(R)_2$, wherein said $-C_1-C_{20}$ alkyl, $-C_1-C_8$ heteroalkyl, $-C_3-C_8$ carbocyclyl and $-C_1-C_{20}$ alkyl $N(R)_2$ are optionally substituted with 1 to 3 substituents independently selected from R;

10 L^1 and L^2 are each independently a direct bond; and


T is $-C(A^1)X^1-T^2-X^1C(B^1)-$, where T^2 is:



15 wherein each X^1 is a bond, wherein A^1 and B^1 are each independently $=O$, wherein g and j are each independently 0 and m is 1, and wherein D is $-C_3-C_8$ carbocyclo is optionally substituted with $-NH_2$, $-N(R)C(O)H$ or $-N(R)C(O)OH$.

9. The compound of any of claims 2 and 4, or a pharmaceutically acceptable salt or solvate thereof, wherein:

20 L^A is selected from the group consisting of $-halo$, $-N(R)_2$, $-CON(R)_2$, $-S$ -aryl optionally substituted with $-NO_2$ or $-CON(R)_2$, $-S$ -heteroaryl optionally substituted with $-NO_2$, alkyl- SO_2 -heteroaryl, aryl SO_2 -heteroaryl-, and




- L^B is $L^{B1}-L^{B2}-L^{B3}$ wherein L^{B1} is absent or is one or more components selected from the group consisting of -C(O)-, -C(S)-, -C(O)NR-, -C(O)C₁-C₆alkyl-, -C(O)NRC₁-C₆alkyl-, -C₁-C₆alkyl(OCH₂CH₂)₁₋₆-, -C(O)C₁-C₆alkylNRC(O)-, -C(O)C₁-C₆alkyl(OCH₂CH₂)₁₋₆-, -C₁-C₆alkyl(OCH₂CH₂)₁₋₆-C(O)-, -C₁-C₆alkyl-S-S-C₁-C₆alkylNRC(O)CH₂-,
- 5 -C₁-C₆alkyl(OCH₂CH₂)₁₋₆NRC(O)CH₂-, -C(O)C₁-C₆alkyl-NRC(O)C₁₋₆alkyl-, -C(O)-C₁-C₆alkyl(OCH₂CH₂)₁₋₆NRC(O)-, -C(O)C₁-C₆alkyl-phenyl(NR-C(O)C₁-C₆alkyl)₁₋₄-, -C(O)C₁-C₆alkyl(OCH₂CH₂)₁₋₆-NRC(O)C₁-C₆alkyl-, -C₁-C₆alkyl-, -S-, -C(O)-CH(NR-C(O)C₁-C₆alkyl)-C₁-C₆alkyl- and (-CH₂-CH₂-O-) ₁₋₂₀, wherein L^{B2} is AA₀₋₁₂, wherein AA is a natural amino acid, a non-natural amino acid or -(CR¹⁵)_o-S-S-(CR¹⁵)_p where o and p are each
- 10 independently an integer from 1 to 20, and L^{B3} is -PABA-, -PABC-, -C(O)(CH₂)_nC(O)- or absent; and

L^C is absent.

10. The compound of any of claims 3 and 5, or a pharmaceutically acceptable salt or solvate thereof, wherein:




- 15 L^A is selected from: a bond to AB, -NR-(bond to AB),





- L^B is $L^{B1}-L^{B2}-L^{B3}$ wherein L^{B1} is absent or is one or more components selected from the group consisting of -C(O)-, -C(S)-, -C(O)NR-, -C(O)C₁-C₆alkyl-, -C(O)NRC₁-C₆alkyl-, -C₁-C₆alkyl(OCH₂CH₂)₁₋₆-, -C(O)C₁-C₆alkylNRC(O)-, -C(O)C₁-C₆alkyl(OCH₂CH₂)₁₋₆-,
- 20 -C₁-C₆alkyl(OCH₂CH₂)₁₋₆-C(O)-, -C₁-C₆alkyl-S-S-C₁-C₆alkylNRC(O)CH₂-, -C₁-C₆alkyl(OCH₂CH₂)₁₋₆NRC(O)CH₂-, -C(O)C₁-C₆alkyl-NRC(O)C₁₋₆alkyl-, -C(O)-C₁-C₆alkyl(OCH₂CH₂)₁₋₆NRC(O)-, -C(O)C₁-C₆alkyl-phenyl(NR-C(O)C₁-C₆alkyl)₁₋₄-, -C(O)C₁-C₆alkyl(OCH₂CH₂)₁₋₆-NRC(O)C₁-C₆alkyl-, -C₁-C₆alkyl-, -S-, -C(O)-CH(NR-C(O)C₁-C₆alkyl)-C₁-C₆alkyl- and (-CH₂-CH₂-O-) ₁₋₂₀, wherein L^{B2} is AA₀₋₁₂, wherein AA is a natural
- 25 amino acid, a non-natural amino acid or -(CR¹⁵)_o-S-S-(CR¹⁵)_p where o and p are each independently an integer from 1 to 20, and L^{B3} is -PABA-, -PABC-, -C(O)(CH₂)_nC(O)- or absent; and



L^C is absent.







11. A compound according to Claim 1, or a pharmaceutically acceptable salt or solvate thereof, selected from:






12. A compound according to Claim 1, or a pharmaceutically acceptable salt or solvate thereof, selected from:






where Pg is H, acyl, PO_3H_2 , or glycosyl.





13. A compound according to Claim 2, or a pharmaceutically acceptable salt or solvate thereof, selected from:




14. A compound according to Claim 2, or a pharmaceutically acceptable salt or solvate thereof, comprising a payload and a linker, said payload selected from:



5 and said linker is selected from:



, and



where

P represents the point of attachment to said payload,

each R^7 is independently H or $-C_1-C_{20}$ alkyl,


R^8 is $-C_1-C_{20}$ alkyl, $-C_6-C_{14}$ aryl or $-C_6-C_{14}$ heteroaryl,

5 Pg is H, acyl, PO_3H_2 , or glycosyl,





n = 0-20, and

m = 0-20.


15. A compound according to Claim 2, or a pharmaceutically acceptable salt or solvate thereof, comprising a payload and a linker, said payload selected from:



10 and said linker is selected from:



, and



,

where

- 5 P represents the point of attachment to said payload,

each R⁷ is independently H or -C₁-C₂₀ alkyl,


R⁸ is -C₁-C₂₀ alkyl, -C₆-C₁₄ aryl or -C₆-C₁₄ heteroaryl,

Pg is H, acyl, PO₃H₂, or glycosyl,

$n = 0-20$, and




5 $m = 0-20$.


16. A compound according to Claim 3, or a pharmaceutically acceptable salt or solvate thereof, selected from:









and wherein X is an antibody selected from the group consisting of IL13R α 2-AB08-v1.0, CD33-11A1-v1417-hG1-(C), CD33-11A1-v1417-K334C-K392C-hG1-(C334+C392), and CD33-11A1-v1417-K334C-hG1-(C334).


17. A compound according to Claim 3, or a pharmaceutically acceptable salt or solvate thereof, selected from:















and



where AB is an antibody.

18. The compound of claim 17, or a pharmaceutically acceptable salt or solvate thereof, wherein said antibody AB is selected from trastuzumab, trastuzumab mutants, oregovomab, edrecolomab, cetuximab, a humanized monoclonal antibody to the vitronectin receptor ($\alpha v\beta 3$), alemtuzumab, anti HLA DR antibodies, 131I Lym 1, anti HLA Dr10 antibodies, anti cd33 antibodies, anti cd22 antibodies, labetuzumab, bevacizumab, ibritumomab tiuxetan, ofatumumab, panitumumab, rituximab, tositumomab, ipilimumab, and gemtuzumab.
19. A linker payload or an antibody drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, comprising a radical of a compound of Claim 11 or Claim 12.
20. An antibody drug conjugate, or a pharmaceutically acceptable salt or solvate thereof, comprising a radical of a compound of any one of Claims 13 to 15.
21. A pharmaceutical composition comprising a compound of any one of Claims 1 to 20 or a pharmaceutically acceptable salt or solvate thereof, and pharmaceutically acceptable excipient.
22. A compound according to any one of Claims 1 to 20, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of Claim 21, for use in the treatment of cancer.
23. A compound, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition for use according to claim 22, wherein said cancer is bladder cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, kidney cancer, lung cancer, esophageal cancer, ovarian cancer, prostate cancer, pancreatic cancer, skin cancer, stomach (gastric) cancer, testicular cancer, leukemias and lymphomas.